These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21266847)

  • 21. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
    Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Characterization and Comparison of
    Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
    Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
    [No Abstract]   [Full Text] [Related]  

  • 25. Current developments in malaria transmission-blocking vaccines.
    Stowers A; Carter R
    Expert Opin Biol Ther; 2001 Jul; 1(4):619-28. PubMed ID: 11727498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pfs230: from malaria transmission-blocking vaccine candidate toward function.
    Williamson KC
    Parasite Immunol; 2003 Jul; 25(7):351-9. PubMed ID: 14521577
    [No Abstract]   [Full Text] [Related]  

  • 27. Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants.
    Voepel N; Boes A; Edgue G; Beiss V; Kapelski S; Reimann A; Schillberg S; Pradel G; Fendel R; Scheuermayer M; Spiegel H; Fischer R
    Biotechnol J; 2014 Nov; 9(11):1435-45. PubMed ID: 25200253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
    Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
    Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate.
    Sookpongthai P; Utayopas K; Sitthiyotha T; Pengsakul T; Kaewthamasorn M; Wangkanont K; Harnyuttanakorn P; Chunsrivirot S; Pattaradilokrat S
    Parasit Vectors; 2021 Nov; 14(1):571. PubMed ID: 34749796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
    Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC
    J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor CD4
    Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
    Front Immunol; 2021; 12():732667. PubMed ID: 34659219
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission-blocking immunity against malaria and other vector-borne diseases.
    Kaslow DC
    Curr Opin Immunol; 1993 Aug; 5(4):557-65. PubMed ID: 8216932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
    Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
    Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
    Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.
    Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC
    Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.